Timothy S Fenske1, Mei-Jie Zhang, Jeanette Carreras, Ernesto Ayala, Linda J Burns, Amanda Cashen, Luciano J Costa, César O Freytes, Robert P Gale, Mehdi Hamadani, Leona A Holmberg, David J Inwards, Hillard M Lazarus, Richard T Maziarz, Reinhold Munker, Miguel-Angel Perales, David A Rizzieri, Harry C Schouten, Sonali M Smith, Edmund K Waller, Baldeep M Wirk, Ginna G Laport, David G Maloney, Silvia Montoto, Parameswaran N Hari. 1. Timothy S. Fenske and Mehdi Hamadani, Medical College of Wisconsin; Mei-Jie Zhang, Jeanette Carreras, and Parameswaran N. Hari, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Ernesto Ayala, H. Lee Moffitt Cancer Center and Research Institute, Tampa; Baldeep M. Wirk, Shands Healthcare and University of Florida, Gainesville, FL; Linda J. Burns, University of Minnesota Medical Center, Fairview, Minneapolis; David J. Inwards, Mayo Clinic Rochester, Rochester, MN; Amanda Cashen, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO; Luciano J. Costa, Medical University of South Carolina, Charleston, SC; César O. Freytes, South Texas Veterans Health Care System and University of Texas Health Science Center, San Antonio, TX; Robert P. Gale, Imperial College; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Leona A. Holmberg and David G. Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA; Hillard M. Lazarus, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Reinhold Munker, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA; Miguel-Angel Perales, Memorial Sloan-Kettering Cancer Center, New York, NY; David A. Rizzieri, Duke University Medical Center, Durham, NC; Harry C. Schouten, Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; Sonali M. Smith, University of Chicago Hospitals, Chicago, IL; Edmund K. Waller, Emory University Hospital, Atlanta, GA; and Ginna G. Laport, Stanford Hospital and Clinics, Stanford, CA.
Abstract
PURPOSE: To examine the outcomes of patients with chemotherapy-sensitive mantle-cell lymphoma (MCL) following a first hematopoietic stem-cell transplantation (HCT), comparing outcomes with autologous (auto) versus reduced-intensity conditioning allogeneic (RIC allo) HCT and with transplantation applied at different times in the disease course. PATIENTS AND METHODS: In all, 519 patients who received transplantations between 1996 and 2007 and were reported to the Center for International Blood and Marrow Transplant Research were analyzed. The early transplantation cohort was defined as those patients in first partial or complete remission with no more than two lines of chemotherapy. The late transplantation cohort was defined as all the remaining patients. RESULTS: Auto-HCT and RIC allo-HCT resulted in similar overall survival from transplantation for both the early (at 5 years: 61% auto-HCT v 62% RIC allo-HCT; P = .951) and late cohorts (at 5 years: 44% auto-HCT v 31% RIC allo-HCT; P = .202). In both early and late transplantation cohorts, progression/relapse was lower and nonrelapse mortality was higher in the allo-HCT group. Overall survival and progression-free survival were highest in patients who underwent auto-HCT in first complete response. Multivariate analysis of survival from diagnosis identified a survival benefit favoring early HCT for both auto-HCT and RIC allo-HCT. CONCLUSION: For patients with chemotherapy-sensitive MCL, the optimal timing for HCT is early in the disease course. Outcomes are particularly favorable for patients undergoing auto-HCT in first complete remission. For those unable to achieve complete remission after two lines of chemotherapy or those with relapsed disease, either auto-HCT or RIC allo-HCT may be effective, although the chance for long-term remission and survival is lower.
PURPOSE: To examine the outcomes of patients with chemotherapy-sensitive mantle-cell lymphoma (MCL) following a first hematopoietic stem-cell transplantation (HCT), comparing outcomes with autologous (auto) versus reduced-intensity conditioning allogeneic (RIC allo) HCT and with transplantation applied at different times in the disease course. PATIENTS AND METHODS: In all, 519 patients who received transplantations between 1996 and 2007 and were reported to the Center for International Blood and Marrow Transplant Research were analyzed. The early transplantation cohort was defined as those patients in first partial or complete remission with no more than two lines of chemotherapy. The late transplantation cohort was defined as all the remaining patients. RESULTS: Auto-HCT and RIC allo-HCT resulted in similar overall survival from transplantation for both the early (at 5 years: 61% auto-HCT v 62% RIC allo-HCT; P = .951) and late cohorts (at 5 years: 44% auto-HCT v 31% RIC allo-HCT; P = .202). In both early and late transplantation cohorts, progression/relapse was lower and nonrelapse mortality was higher in the allo-HCT group. Overall survival and progression-free survival were highest in patients who underwent auto-HCT in first complete response. Multivariate analysis of survival from diagnosis identified a survival benefit favoring early HCT for both auto-HCT and RIC allo-HCT. CONCLUSION: For patients with chemotherapy-sensitive MCL, the optimal timing for HCT is early in the disease course. Outcomes are particularly favorable for patients undergoing auto-HCT in first complete remission. For those unable to achieve complete remission after two lines of chemotherapy or those with relapsed disease, either auto-HCT or RIC allo-HCT may be effective, although the chance for long-term remission and survival is lower.
Authors: Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Trumper; Marcel Reiser; Hannes Wandt; Eva Lengfelder; Michael Unterhalt; Wolfgang Hiddemann Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: Lihua E Budde; Katherine A Guthrie; Brian G Till; Oliver W Press; Thomas R Chauncey; John M Pagel; Steven H Petersdorf; William I Bensinger; Leona A Holmberg; Andrei R Shustov; Damian J Green; David G Maloney; Ajay K Gopal Journal: J Clin Oncol Date: 2011-07-05 Impact factor: 44.544
Authors: Gordon Cook; Graeme M Smith; Keiren Kirkland; Julia Lee; Rachel Pearce; Kirsty Thomson; Emma Morris; Kim Orchard; Simon Rule; Nigel Russell; Charles Craddock; David I Marks Journal: Biol Blood Marrow Transplant Date: 2010-04-24 Impact factor: 5.742
Authors: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2005-01-24 Impact factor: 44.544
Authors: Thomas E Witzig; Susan M Geyer; Irene Ghobrial; David J Inwards; Rafael Fonseca; Paul Kurtin; Stephen M Ansell; Ronnie Luyun; Patrick J Flynn; Roscoe F Morton; Shaker R Dakhil; Howard Gross; Scott H Kaufmann Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Elisabeth Vandenberghe; Carmen Ruiz de Elvira; Fausto R Loberiza; E Conde; A López-Guillermo; C Gisselbrecht; F Guilhot; Julie M Vose; Koen van Biesen; J Douglas Rizzo; Dennis D Weisenburger; Peter Isaacson; Mary M Horowitz; Anthony H Goldstone; Hillard M Lazarus; Norbert Schmitz Journal: Br J Haematol Date: 2003-03 Impact factor: 6.998
Authors: Mehdi Hamadani; Wael Saber; Kwang Woo Ahn; Jeanette Carreras; Mitchell S Cairo; Timothy S Fenske; Robert Peter Gale; John Gibson; Gregory A Hale; Parameswaran N Hari; Jack W Hsu; David J Inwards; Rammurti T Kamble; Anderas Klein; Dipnarine Maharaj; David I Marks; David A Rizzieri; Bipin N Savani; Harry C Schouten; Edmund K Waller; Baldeep Wirk; Hillard M Lazarus Journal: Biol Blood Marrow Transplant Date: 2013-01-17 Impact factor: 5.742
Authors: Roswitha Forstpointner; Martin Dreyling; Roland Repp; Sandra Hermann; Annette Hänel; Bernd Metzner; Christiane Pott; Frank Hartmann; Frank Rothmann; Robert Rohrberg; Hans-Peter Böck; Hannes Wandt; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-07-29 Impact factor: 22.113
Authors: Michael B Maris; Brenda M Sandmaier; Barry E Storer; Thomas Chauncey; Monic Jain Stuart; Richard T Maziarz; Edward Agura; Amelia A Langston; Michael Pulsipher; Rainer Storb; David G Maloney Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: S Robinson; P Dreger; D Caballero; P Corradini; C Geisler; M Ghielmini; S Le Gouill; E Kimby; S Rule; U Vitolo; M Dreyling; O Hermine Journal: Leukemia Date: 2014-07-18 Impact factor: 11.528
Authors: K Horstmann; A Boumendil; J Finke; H Finel; E Kanfer; G Milone; N Russell; A Bacigalupo; Y Chalandon; J L Diez-Martin; N Ifrah; M Jurado Chacon; P Dreger Journal: Bone Marrow Transplant Date: 2015-03-09 Impact factor: 5.483
Authors: Zanetta S Lamar; Andrew Dothard; LeAnne Kennedy; Scott Isom; Mac Robinson; Rakhee Vaidya; David Hurd; Donald McClain; Glenn Lesser Journal: Leuk Lymphoma Date: 2017-12-18
Authors: M A Kharfan-Dabaja; N El-Jurdi; E Ayala; A S Kanate; B N Savani; M Hamadani Journal: Bone Marrow Transplant Date: 2017-04-03 Impact factor: 5.483
Authors: Timothy S Fenske; Mehdi Hamadani; Jonathon B Cohen; Luciano J Costa; Brad S Kahl; Andrew M Evens; Paul A Hamlin; Hillard M Lazarus; Effie Petersdorf; Christopher Bredeson Journal: Biol Blood Marrow Transplant Date: 2016-04-27 Impact factor: 5.742